TABLE 2.

Dual targeting of GyrB and ParE by VRT-125853 and VRT-752586^a

Strain	GyrB	ParE (GrlB)	MIC (μg/ml)
			VRT-125853	VRT-752586	Novo	Cipro
S. aureus ATCC 29213b	WT	WT	2	0.03	0.13	0.25
	T173N	WT	16	0.5	0.25	0.25
	T173I	WT	16	0.5	1	0.25
	R144Ic	WT	4	0.06	8	0.25
	T173N	T166A	>64	>8	0.25	0.25
	T173I	T166A	>64	4	2	0.25
S. pneumoniae ATCC BAA-255	WT	WT	0.5	0.004	0.5	0.5
	S127Lc	WT	0.5	0.002	8	0.25
	WT	T172A	8	0.016	0.5	0.25
	WT	T172I	4	0.016	0.5	0.5
	T172A	T172A	64	0.25	4	0.25
E. faecalis ATCC 29212	WT	WT	1	0.032	8	1
	WT	T169A	8	0.064	8	1
	T167A	WT	0.5	0.032	16	0.5
	T167I	WT	1	0.064	32	1
	T167I	T169A	>64	1	16	0.5
	T167A	T169A	>64	0.5	16	0.5
H. influenzae ATCC 51907	WT	WT	4	1	0.064	0.004
	R140Cc	WT	2	1	8	0.004
	R140Hc	WT	2	1	4	0.004
	R140Lc	WT	4	1	4	0.004
	T169I	WT	>64	>64	0.25	0.004

^aAbbreviations: WT, wild type; Novo, novobiocin; Cipro, ciprofloxacin.

^bIn S. aureus, ParE is GrlB.

^cMutants selected with novobiocin.